PTO/SB/08A (10-01)

OCT 2 8 2004 Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB Under the Papen control number.

Substitute for form 1449APTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

Complete if Known		
Application Number	10/767,471	
Filing Date	January 30, 2004	
First Named Inventor	Michele CARGILL, et al.	
Art Unit	1645	
Examiner Name	TBA	
Attorney Docket Number	CI 001505	

U.S. PATENT DOCUMENTS					
Examiner Initials		Document Number Number-Kind Code <sup>2</sup> (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passeges or Relevant Figures Appear
· · · · ·		US- US- US-			
· · · · · ·		US- US- US- US-			
		US- US- US-			
		US- US- US-			
		US- US- US-	· · · · · · · · · · · · · · · · · · ·		
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code3 - Number4 - Kind Code3 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages or Relevent Figures Appear	   T <sup>1</sup>
STK STK		WO 01/11084 A WO 02/074989 A	02-15-2001 09-26-2002	KIMBERLY, R. P., et al. GOUGH, S., et al.		
						Γ.
						ļ. •
						ļ.,
			·			

Examiner /Stephen Kapushoc/	Date Considered	12/05/2006
-----------------------------	--------------------	------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional).

2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.

3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible.

6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ons are required to respond to a collection of information unless it contains a valid OMB organ Act of 1995, no pac

TRADENAS Substitute for form 1449B/PTO

Under the Paperwork Reducentrol number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of - 2 Sheet

Complete If Known			
Application Number	10/767,471		
Filing Date	January 30, 2004		
First Named Inventor	Michele CARGILL, et al.		
Group Art Unit	1645		
Examiner Name	ТВА		
Attorney Docket Number	CL001505		

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), nublisher, city and/or country where outlished.	Ţ
STK		Database Genbank Retrieved on 12.07.04 6 July 2000, "Human DNA Sequence from Clone RP11-179A5 on Chromosome 1" Database Accession No. AL365225	
		MORGAN, Ann W. et al., "Fegamma Receptor Type IIIA is associated with Rheumatoid Arthritis in Two Distinct Ethnic Groups". Arthritis and Rheumatism, vol. 43, no. 10,	
		WALDON-LYNCH F. et al., "Turnour Necrosis Factor 5' Promoter Single Nucleotide Polymorphisms Influence Susceptibility to Reheumatoid Arthritis (RA) in Immunogenetically Defined Multiplex RA Families", Genes and Immunity, April 2001, Pages 82-87	_
		YAMADA, R. et al., "Association between a Single-Nucleotide Polymorphism in the Promoter of the Human Interleukin-3 Gene and Rheumatoid Arthritis in Japanese Patients and Maximum-Likelihood Estimation of Effect that Two Genetic Loci Have on Susceptibility to the Diseases", American Journal of Human Genetics, American Society of Human Genetics, Chicago, IL, U.S., vol. 68, no. 3, 2001, pages 674-685	-
		Copy of International Search Report dated October 19, 2004	
$\downarrow$		Copy of Written Opinion dated October 19, 2004	
	1		1

Examiner Signature	/Stephen Kapushoc/	Date Considered	12/05/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).
Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.